Home › Trial NCT01951157
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
- Trial IDNCT01951157
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorPharmaMar
- Enrollment69
- Start date2013-09-11
- ConditionsNon-Small Cell Lung Cancer (NSCLC)
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.